弗拉辛通过调节氧化应激,炎症和TLR4/NF-κB和MAPK信号通路来改善性结肠炎
Alternative therapies in health and medicine
|March 22, 2024
概括
来自Cortex Fraxini的化合物fraxin通过向氧化应激和关键信号通路,有效地减少性结肠炎 (UC) 症状和炎症. 这表明Fraxin是UC的潜在新疗法.
科学领域:
- 药理学和胃肠病学 药理学和胃肠病学
- 自然产品化学 自然产品化学
- 炎症研究 炎症研究
背景情况:
- 性结肠炎 (UC) 是一种慢性胃肠道疾病,治疗选择有限.
- 弗拉克辛是Cortex Fraxini (Qinpi) 的一个关键成分,已经证明了治疗潜力.
- 弗拉克辛对UC病变的作用在很大程度上仍未被探索.
研究的目的:
- 在DSS诱导的UC的小鼠模型中研究Fraxin的治疗潜力.
- 阐明Fraxin发挥抗炎作用的潜在分子机制.
主要方法:
- 使用LPS诱导的RAW264.7巨体进行了体外研究.
- 在体内研究使用DSS诱导的大肠炎的小鼠模型.
- 测试包括ELISA,西式涂抹和氧化应激标志物的测量.
主要成果:
- 弗拉辛显著缓解了UC症状,包括减肥,缩小结肠长度和改善组织学.
- 弗拉辛抑制了反应性氧物种 (ROS) 的产生和促炎性细胞因子的产生.
- 弗拉辛调节了TLR4/NF-κB和MAPK信号通路,减少了关键的炎症介导体.
结论:
- 弗拉克辛在改善DSS诱导的小鼠肠道炎症方面表现出显著的疗效.
- 治疗效果归因于氧化应激,炎症和关键信号通路的调节.
- 弗拉克辛是治疗性结肠炎的一种有前途的新型治疗剂.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Bowel Disease I: Ulcerative Colitis
179
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
179
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331


